Please login to the form below

SNG001

This page shows the latest SNG001 news and features for those working in and with pharma, biotech and healthcare.

UK biotech Synairgen treats first patient in phase 3 COVID-19 trial

SNG001 delivers an inhaled formulation of Interferon-beta-1a directly to the lungs. ... SNG001 delivers an inhaled formulation of Interferon-beta-1a (INF-beta-1a) to the lungs directly via nebulisation.

Latest news

Synairgen’s SNG001 advances into phase 3 COVID-19 trial

Southampton, UK-based biotech company Synairgen has announced that a small phase 2 trial of its investigational candidate SNG001 supports advancement into phase 3 testing. ... Further, 58% of the patients in the SNG001 group had recovered on day 28,
Positive COPD data for Synairgen's SNG001 supports COVID-19 programme

Interim analysis from the phase 2 trial in COPD patients with confirmed respiratory viral infection found that treatment with SNG001 improved lung antiviral responses compared to placebo. ... In exacerbating patients who already required treatment with
UK biotech Synairgen reveals promising early results for COVID-19 drug

The double-blind, placebo-controlled phase 1 trial of SNG001 recruited 101 hospitalised COVID-19 patients from nine hospital sites across the UK. ... While three patients died after being randomised to receive the placebo, no deaths were observed among
UK biotech Synairgen to begin COVID-19 trial of lead candidate

SNG001 (inhaled formulation of interferon-beta-1a), as concerns grow in the UK that COVID-19 cases could soar in the comings weeks. ... SNG001 delivers a formulation of INF-beta-1a to the lungs directly via nebulisation, and is suitable for inhaled
AZ licenses asthma infection drug from Synairgen

The novel formulation - called SNG001 - is designed to prevent the sometimes severe exacerbations suffered by asthma patients when they develop respiratory viral infections such as colds. ... The big pharma company will also meet all future development

More from news
Approximately 4 fully matching, plus 2 partially matching documents found.

Latest Intelligence

Pharma deals during June 2014

Clearly not deterred by this, AZ has moved on to build on its respiratory franchise by in-licensing Synairgen's inhaled beta interferon SNG001.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Healthcare Lead Copywriter: Competitive

Account Director – Creative Healthcare Communications: Competative

Healthcare Senior Account Manager: Competitive

Healthcare Account Director: Competitive

Account Manager Healthcare / Pharmaceutical Sector: Negotiable Salary

Commercial Finance Director, Healthcare Marketing Communications...: up to £90K

Medical Editor: Competitive

Sales Director, Healthcare communications agency, London/ SE UK: Six figure salary

PMHub

Add my company

Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Mistrust in medical research: a patient perspective: The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease: Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients: We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...